{"id":"lumify","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival blanching"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Mydriasis"}]},"_chembl":null,"_dailymed":{"setId":"022de945-0b26-40ae-8e88-d3fe2464d106","title":"LUMIFY REDNESS RELIEVER EYE DROPS (BRIMONIDINE TARTRATE) SOLUTION/ DROPS [BAUSCH & LOMB INCORPORATED]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brimonidine tartrate, the active ingredient in Lumify, selectively binds to alpha-1 adrenergic receptors on the conjunctival and episcleral blood vessels of the eye. This causes vasoconstriction, reducing blood flow to the conjunctiva and thereby decreasing the appearance of redness. The effect is rapid and temporary, typically lasting 8 hours.","oneSentence":"Lumify is a selective alpha-1 adrenergic receptor agonist that constricts blood vessels in the eye to reduce redness.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:46.120Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reduction of conjunctival redness due to minor eye irritation"}]},"trialDetails":[{"nctId":"NCT07074782","phase":"","title":"Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues","status":"NOT_YET_RECRUITING","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2026-01","conditions":"Glaucoma","enrollment":1500},{"nctId":"NCT06803654","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2025-05-22","conditions":"Ocular Redness","enrollment":578},{"nctId":"NCT05591755","phase":"PHASE3","title":"Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2022-11-18","conditions":"Seasonal Allergic Conjunctivitis","enrollment":229},{"nctId":"NCT04944290","phase":"PHASE3","title":"To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2021-05-28","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":447},{"nctId":"NCT06078592","phase":"PHASE4","title":"Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensive","status":"COMPLETED","sponsor":"CHA University","startDate":"2021-10-08","conditions":"Glaucoma, Ocular Hypertensive","enrollment":60},{"nctId":"NCT03193333","phase":"PHASE3","title":"PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2017-11-06","conditions":"Primary Open-angle Glaucoma","enrollment":51},{"nctId":"NCT06486467","phase":"NA","title":"Reliability of Minimally Trained Operator's Velocity-Time Integral Measurement Guided by Artificial Intelligence VTI","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-11-14","conditions":"Velocity-time Integral Measurement, Critically Ill Patients, Tissue Hypoperfusion","enrollment":100},{"nctId":"NCT05360784","phase":"PHASE3","title":"\"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness\"","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2022-05-13","conditions":"Ocular Redness","enrollment":380},{"nctId":"NCT03235232","phase":"PHASE3","title":"BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension","status":"COMPLETED","sponsor":"EMS","startDate":"2021-02-01","conditions":"Ocular Hypertension, Primary Open-angle Glaucoma","enrollment":406},{"nctId":"NCT04702789","phase":"PHASE4","title":"Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-10-19","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":28},{"nctId":"NCT02623023","phase":"NA","title":"Prophylaxis for Anti-VEGF-induced IOP Elevation","status":"WITHDRAWN","sponsor":"McMaster University","startDate":"2019-01-01","conditions":"Ocular Hypertension","enrollment":""},{"nctId":"NCT03508869","phase":"NA","title":"Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea","status":"TERMINATED","sponsor":"Skin Laser & Surgery Specialists","startDate":"2016-09-27","conditions":"Erythema and Flushing Associated With Rosacea","enrollment":5},{"nctId":"NCT01659853","phase":"PHASE3","title":"Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2012-09","conditions":"Erythema, Rosacea","enrollment":70},{"nctId":"NCT02249065","phase":"PHASE4","title":"Mirvaso in Use Study","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2014-09","conditions":"Rosacea","enrollment":205},{"nctId":"NCT03450629","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of PDP-716","status":"COMPLETED","sponsor":"Sun Pharma Advanced Research Company Limited","startDate":"2018-09-13","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":682},{"nctId":"NCT03220490","phase":"NA","title":"Efficacy and Necessity of Time Interval Between Instillation of Two Glaucoma Eye Drops","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2017-11-01","conditions":"Glaucoma, Glaucoma; Drugs","enrollment":65},{"nctId":"NCT02637232","phase":"","title":"Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2015-10","conditions":"Rosacea","enrollment":301},{"nctId":"NCT04344418","phase":"NA","title":"Harnessing Alternative Resources to Aid Kenyans With Acute Illness","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2020-06-01","conditions":"Cardiorespiratory Failure","enrollment":732},{"nctId":"NCT02289352","phase":"PHASE3","title":"Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2014-07","conditions":"Rosacea","enrollment":462},{"nctId":"NCT03966365","phase":"PHASE1","title":"Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2019-05-02","conditions":"Glaucoma","enrollment":24},{"nctId":"NCT03257813","phase":"PHASE3","title":"Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2016-04-01","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":60},{"nctId":"NCT01062971","phase":"PHASE2","title":"Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2006-02","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":124},{"nctId":"NCT02730871","phase":"PHASE4","title":"Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2016-06-24","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":173},{"nctId":"NCT01170884","phase":"PHASE4","title":"Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-12","conditions":"Glaucoma, Ocular Hypertension","enrollment":121},{"nctId":"NCT00811850","phase":"PHASE4","title":"Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-12","conditions":"Glaucoma","enrollment":15},{"nctId":"NCT02087085","phase":"PHASE2","title":"A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration","status":"TERMINATED","sponsor":"Allergan","startDate":"2014-05-09","conditions":"Geographic Atrophy, Macular Degeneration","enrollment":310},{"nctId":"NCT00735449","phase":"PHASE4","title":"Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":204},{"nctId":"NCT03173365","phase":"PHASE2","title":"The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients","status":"TERMINATED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2017-07-10","conditions":"Hand-foot Syndrome","enrollment":2},{"nctId":"NCT02419508","phase":"PHASE4","title":"SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-08-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":290},{"nctId":"NCT02863705","phase":"PHASE4","title":"Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-07-05","conditions":"Glaucoma, Open-Angle, Normal Tension Glaucoma","enrollment":118},{"nctId":"NCT00658619","phase":"PHASE2","title":"Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-05-01","conditions":"Macular Degeneration","enrollment":119},{"nctId":"NCT02770248","phase":"PHASE4","title":"24-hr Intraocular Pressure Control With SIMBRINZA ®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2016-05-23","conditions":"Glaucoma","enrollment":162},{"nctId":"NCT03513172","phase":"NA","title":"Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy","status":"COMPLETED","sponsor":"University of Toronto","startDate":"2016-12-15","conditions":"Post-Injection Intraocular Pressure Spikes","enrollment":55},{"nctId":"NCT02856919","phase":"PHASE4","title":"A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema.","status":"COMPLETED","sponsor":"Galderma Brasil Ltda.","startDate":"2016-06-13","conditions":"Chronic Persistent Vascular Facial Erythema","enrollment":101},{"nctId":"NCT01217606","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-01","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":185},{"nctId":"NCT01518244","phase":"PHASE4","title":"Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-12","conditions":"Glaucoma","enrollment":50},{"nctId":"NCT01937312","phase":"PHASE4","title":"Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":282},{"nctId":"NCT01937299","phase":"PHASE4","title":"Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":307},{"nctId":"NCT01080209","phase":"PHASE2","title":"Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-02","conditions":"Patients Who Participated in an Intravitreal Brimo PS DDS® Study","enrollment":215},{"nctId":"NCT00275756","phase":"NA","title":"Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans","status":"WITHDRAWN","sponsor":"Medical University of Vienna","startDate":"2008-09","conditions":"Glaucoma","enrollment":""},{"nctId":"NCT00706927","phase":"NA","title":"Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2006-01","conditions":"Retina, Ocular Physiology","enrollment":16},{"nctId":"NCT01241240","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-03","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":192},{"nctId":"NCT02003534","phase":"PHASE4","title":"A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-07","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":376},{"nctId":"NCT01415401","phase":"PHASE4","title":"Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-09","conditions":"Glaucoma, Ocular Hypertension, Open-angle Glaucoma","enrollment":57},{"nctId":"NCT01987752","phase":"","title":"Safety and Efficacy of Combigan® Ophthalmic Solution in Korea","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-01","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":732},{"nctId":"NCT01525173","phase":"PHASE4","title":"A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":137},{"nctId":"NCT01514734","phase":"PHASE4","title":"Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2012-03","conditions":"Glaucoma","enrollment":9},{"nctId":"NCT01229410","phase":"PHASE1","title":"Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-12","conditions":"Vitrectomy","enrollment":24},{"nctId":"NCT01297517","phase":"PHASE3","title":"Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-02","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":1001},{"nctId":"NCT00661479","phase":"PHASE1, PHASE2","title":"An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-07","conditions":"Retinitis Pigmentosa","enrollment":21},{"nctId":"NCT00972374","phase":"PHASE2","title":"Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-11","conditions":"Rhegmatogenous Macula-off Retinal Detachment","enrollment":44},{"nctId":"NCT00693485","phase":"PHASE2","title":"Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-09","conditions":"Glaucoma, Open-Angle","enrollment":70},{"nctId":"NCT00800540","phase":"PHASE4","title":"Circadian Ocular Perfusion Pressure and Ocular Blood Flow","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-02","conditions":"Glaucoma","enrollment":35},{"nctId":"NCT01151904","phase":"PHASE4","title":"Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients","status":"TERMINATED","sponsor":"Allergan","startDate":"2009-11","conditions":"Glaucoma, Angle-Closure","enrollment":17},{"nctId":"NCT01229462","phase":"NA","title":"Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":238},{"nctId":"NCT00457795","phase":"PHASE4","title":"24-hour IOP-lowering Effect of Brimonidine 0.1%","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-12","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":15},{"nctId":"NCT00822055","phase":"PHASE4","title":"Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":140},{"nctId":"NCT00652483","phase":"PHASE3","title":"Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2003-05","conditions":"Glaucoma, Ocular Hypertension","enrollment":433},{"nctId":"NCT00652106","phase":"PHASE3","title":"Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2003-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":432},{"nctId":"NCT00440141","phase":"PHASE4","title":"Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":51,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lumify®","genericName":"Lumify®","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lumify is a selective alpha-1 adrenergic receptor agonist that constricts blood vessels in the eye to reduce redness. Used for Reduction of conjunctival redness due to minor eye irritation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}